肿瘤多药耐药的产生机制及逆转策略

doi:10.3760/cma.j.issn.1673-422X.2013.12.003

摘要/Abstract

摘要： 肿瘤多药耐药(MDR)是导致临床化疗失败和患者死亡的主要原因。研究表明，MDR的发生与P糖蛋白、多药耐药相关蛋白、乳腺癌耐药相关蛋白、肺耐药相关蛋白等多种因素相关。目前MDR的逆转策略主要包括化学药物逆转、基因逆转、免疫逆转、中药逆转和纳米载药系统逆转，并且均取得了一定进展，这将有助于提高肿瘤患者的化疗疗效。

关键词: 肿瘤, 抗药性, 多药, 纳米技术

Abstract: Tumor multidrug resistance (MDR) is the leading cause of clinical chemotherapy failure and death. Researches show that the occurrence of MDR is related to Pglycoprotein, multidrug resistanceassociated proteins, breast cancer resistanceassociated proteins, lung resistancerelated proteins and other factors. Now the reversal strategies of MDR include chemical drugs reversal, gene reversal, immune reversal, traditional Chinese medicine reversal and drugloaded nanosystem reversal, which make some progress and help to improve the effect of cancer chemotherapy.

Key words: Neoplasms, Drug resistance, multiple, Nanotechnology

吴静, 杨睿, 刘树业. 肿瘤多药耐药的产生机制及逆转策略[J]. 国际肿瘤学杂志, 2013, 40(12): 889-892.

WU Jing, YANG Rui, LIU Shu-Ye. Mechanisms and reversal strategies of tumor multidrug resistance[J]. Journal of International Oncology, 2013, 40(12): 889-892.

参考文献

［1］ Wang XB, Wang SS, Zhang QF, et al. Inhibition of tetramethylpyrazine on Pgp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep, 2010, 23(1): 211215. ［2］ Zhao L, Jin X, Xu Y, et al. Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene1. J Exp Clin Cancer Res, 2010, 29(1): 98. ［3］ Wang YL, Yan YL, Zhou NJ, et al. Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP. Chin Med J (Engl), 2010, 123(22): 32993303. ［4］ Lechler P, Renkawitz T, Campean V, et al. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer, 2011, 11: 120. ［5］ Li H, Hui L, Xu W, et al. Modulation of Pglycoprotein expression by triptolide in adriamycinresistant K562/A02 cells. Oncol Lett, 2012, 3(2): 485489. ［6］ Zhang H, Jiang H, Wang X, et al. Reversion of multidrug resistance in tumor by biocompatible nanomaterials. Mini Rev Med Chem, 2010, 10(8): 737745. ［7］ Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATPbinding cassette transporters. Cancer Res, 2010, 70(20): 79817991. ［8］ Imai Y, Yoshimori M, Fukuda K, et al. The PI3K/Akt inhibitor LY294002 reverses BCRPmediated drug resistance without affecting BCRP translocation. Oncol Rep, 2012, 27(6): 17031709. ［9］ Xing AY, Shi DB, Liu W, et al. Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme. Exp Mol Pathol, 2013, 94(3): 481485. ［10］ Shi R, Peng H, Yuan X, et al. Downregulation of cfos by shRNA sensitizes adriamycinresistant MCF7/ADR cells to chemotherapeutic agents via Pglycoprotein inhibition and apoptosis augmentation. J Cell Biochem, 2013, 114(8): 18901900. ［11］ Mosaffa F, Kalalinia F, Parhiz BH, et al. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2overexpressing resistant breast cancer cells compared with their drugsensitive parental line. DNA Cell Biol, 2011, 30(6): 413418. ［12］ Kim DY, Kim MJ, Kim HB, et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of cMyc. Biochim Biophys Acta, 2011, 1812(7): 796805. ［13］ Lu JJ, Cai YJ, Ding J. The shorttime treatment with curcumin sufficiently decreases cells viability, induces apoptosis and copper enhances these effects in multidrugresistant K562/A02 cells. Mol Cell Biochem, 2012, 360(12): 253260. ［14］ Cao SQ, Yin TY, Yang SL. Reversing effects of curcumin on multidrug resistance of Bel7402/5fu cell line. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2012, 32(2): 244247, 252. ［15］ Li SZ, Li K, Zhang JH, et al. The effect of quercetin on doxorubicin cytotoxicity in human breast cancer cells. Anticancer Agents Med Chem, 2013, 13(2): 352355. ［16］ Yuan J, Wong IL, Jiang T, et al. Synthesis of methylated quercetin derivatives and their reversal activities on Pgp and BCRPmediated multidrug resistance tumour cells. Eur J Med Chem, 2012, 54: 413422. ［17］ Lei Y, Tan J, Wink M, et al. An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits Pglycoprotein and multidrug resistanceassociate protein 1. Food Chem, 2013, 136(34): 11171121. ［18］ Luo SX, Deng WY, Wang XF, et al. Molecular mechanism of indirubin3′monoxime and Matrine in the reversal of paclitaxel resistance in NCIH520/TAX25 cell line. Chin Med J (Engl), 2013, 126(5): 925929. ［19］ Chen G, Wang K, Yang BY, et al. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol, 2012, 40(1): 139147. ［20］ Kobayashi E, Lyer AK, Hornicek FJ, et al. Lipidfunctionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin Orthop Relat Res, 2013, 471(3): 915925. ［21］ Zhang Z, Liu Z, Ma L, et al. Reversal of multidrug resistance by mitochondrial targeted selfassembled nanocarrier based on stearylamine. Mol Pharm, 2013, 10(6): 24262434. ［22］ Dreaden EC, Austin LA, Mackey MA, et al. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv, 2012, 3(4): 457478. ［23］ Zhi F, Dong H, Jia X, et al. Functionalized grapheme oxide mediated adriamycin delivery and miR21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS One, 2013, 8(3): e60034. ［24］ Ren F, Chen R, Wang Y, et al. Paclitaxelloaded poly(nbutylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer. Pharm Res, 2011, 28(4): 897906. ［25］ Duan J, Mansour HM, Zhang Y, et al. Reversion of multidrug resistance by coencapsulation of doxorubicin and curcumin in chitosan/poly (butylcyanoacrylate) nanoparticles. Int J Pharm, 2012, 426(12): 193201. ［26］ Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anticancer drug delivery. J Control Release, 2010, 148(2): 135146. ［27］ Huang IP, Sun SP, Cheng SH, et al. Enhanced chemotherapy of cancer using pHsensitive mesoporous silica nanoparticles to antagonize Pglycoproteinmediated drug resistance. Mol Cancer Ther, 2011, 10(5): 761769. ［28］ Gao ZG, Tian L, Hu J, et al. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J Control Release, 2011, 152(1): 8489.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.